COMMUNIQUÉS West-GlobeNewswire
-
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
01/07/2026 -
Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform
01/07/2026 -
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
01/07/2026 -
ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs
01/07/2026 -
Correction: Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares
01/07/2026 -
LiveWorld Names Rob Thomas Vice President, Creative Director to Support Growing Healthcare Creative Practice
01/07/2026 -
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director
01/07/2026 -
Alvotech further strengthens liquidity by securing term loan facility of $75 million
01/07/2026 -
Alvotech further strengthens liquidity by securing term loan facility of $75 million
01/07/2026 -
Urteste S.A. Receives U.S. Patent for the Panuri Test
01/07/2026 -
AB Science : Résultats de l'Assemblée Générale Mixte du 30 juin 2026
01/07/2026 -
Communiqué de presse : Mise en ligne du document «Q2 2026 aide-mémoire »
01/07/2026 -
Ipsen va acquérir Memo Therapeutics AG, élargissant son portefeuille de maladies rares grâce à l’ajout d’un anticorps premier de sa classe ciblant le polyomavirus BK
01/07/2026 -
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
01/07/2026 -
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
01/07/2026 -
Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé
01/07/2026 -
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01/07/2026 -
Press Release: Availability of the aide-mémoire for Q2 2026 results
01/07/2026 -
Idorsia appoints Roland Wandeler as Chief Executive Officer
01/07/2026
Pages